Smartlab Europe

News

Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization (CRO), to conduct a Phase...

Metrics Contract Services Increases Capacity With New Equipment Investment

Metrics Contract Services, the contract pharmaceutical development and manufacturing division of Mayne Pharma, has invested in additional equipment to enhance capacity in drug delivery. A Korsch XM-12 Bilayer Tablet Press and a Top Spray Fluidization system for the Glatt...

Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections

Samsung Biologics, a global contract development and manufacturing organization (CMDO), celebrated the one-year mark of Live Virtual Tour (LVT), a real-time interactive platform to provide remote site inspections for both clients and regulatory agencies. The innovative digital solution was...

va-Q-tec expands worldwide airline partner network with Turkish Cargo

va-Q-tec has secured the air cargo airline Turkish Cargo as another partner within its global network. The airline is currently the fastest growing air cargo carrier in the world. Now, the German company’s thermal containers will continue to move...

Australia recommends AstraZeneca COVID-19 vaccine only for people over 60

The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended the use of the AstraZeneca Covid-19 vaccine in Australia for individuals aged above 60 years. The latest advice is based on the increased risk of illness and death from Covid-19...

European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine, including the ability to purchase other COVID-19 vaccine candidates from Moderna’s...

Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome

Tonix Pharmaceuticals has announced its intention to develop the investigational candidate TNX-102 for the potential treatment of long COVID syndrome – also known as Post-Acute Sequelae of COVID-19 (PASC). Currently, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is in mid-phase 3...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »